Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Invex Therapeutics Ltd. ( (AU:IXC) ) has shared an announcement.
Invex Therapeutics Ltd announced the cessation of Dr. Thomas Duthy as a director, effective November 7, 2025. Dr. Duthy held 285,661 ordinary shares through Emmirato Pty Ltd, where he serves as a director and shareholder. This change in directorship may impact the company’s strategic direction and investor relations, as leadership transitions can influence stakeholder confidence and operational focus.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a company operating in the biotechnology industry, focusing on the development of therapeutic solutions. The company is involved in the research and development of treatments for neurological conditions, aiming to address unmet medical needs in this sector.
Average Trading Volume: 66,235
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$8.64M
For a thorough assessment of IXC stock, go to TipRanks’ Stock Analysis page.